Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Common supplement may shield kidneys from chemo damage

NCT ID NCT07156786

Disease control Sponsor: Fakultas Kedokteran Universitas Indonesia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether N-Acetylcysteine (NAC), a common supplement, can protect kidney function in cancer patients receiving cisplatin chemotherapy. 72 adults will take either NAC or a placebo for seven days around their chemo session. Researchers will measure kidney injury markers in urine and blood to see if NAC helps prevent damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
N-Acetylcysteine (NAC)
What this could lead to
If it works, this could point toward a simple way to reduce kidney damage from cisplatin chemotherapy, helping patients tolerate treatment better.
What could go wrong
This is a small, early-phase trial with only 72 participants. The results may not apply to all patients, and NAC may not provide significant protection or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with cancer/ malignancy proven by histopathological examination * Patient with GFR ≥60 ml/mins/1,73 m² * Patient with normal complete blood count and liver function test result * Patient with good performance status (Karnofsky score ≥80) * Patients with cisplatin based chemotherapy Exclusion Criteria: * Patient that can not tolerate N-Acetylcysteine usage * Patient with history of hypersensitivity to N-Acetylcysteine * Patient that given other potentially nephrotoxic drug, such as furosemide, non-steroidal anti-infammatory drugs, aminoglycosides, amphotericin B, cephalosporine * Patient that given other chemotherapy drug, such as permetrexed, ifosfamide, gemcitabin, bevacizumab, cetuxsimab * Patient with history of malignant or uncontrolled hypertension * patient with congestive heart failure, kidney structure abnormality, and acute infection * Pregnant or lactating women * Patient refusing to participate in the research

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acetylcysteine adverse reaction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acetylcysteine adverse reaction Acute kidney injury Cancer (solid tumors) Kidney function issue Kidney function tests

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.